Literature DB >> 2459295

Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen.

A Townsend1, J Bastin, K Gould, G Brownlee, M Andrew, B Coupar, D Boyle, S Chan, G Smith.   

Abstract

Vaccinia infection interferes with the presentation of influenza Haemagglutinin (HA) and Nucleoprotein (NP) to class I-restricted CTL. The inhibitory effect is selective for certain epitopes, and is more profound during the late phase of infection. For influenza A/NT/60/68 NP, the block is present during both early and late phases of infection, and is selective for the COOH-terminal epitope defined by peptide 366-379, having no detectable effect on the presentation of the NH2-terminal epitope 50-63. The presentation of HA is inhibited only during the late phase of vaccinia infection. For both proteins, presentation is partially (NP) or completely (HA) restored by expression of rapidly degraded protein fragments in the vaccinia infected target cell. For HA, deletion of the NH2-terminal signal sequence completely overcomes the block. For NP, either a large NH2-terminal deletion or the construction of a rapidly degraded ubiquitin-NP fusion protein partially restores presentation. These results illustrate the relationship between degradation of viral proteins in the cytoplasm of an infected cell and recognition of epitopes at the cell surface by class I-restricted T cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2459295      PMCID: PMC2189091          DOI: 10.1084/jem.168.4.1211

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  34 in total

1.  The sequence of the nucleoprotein gene of human influenza A virus, strain A/NT/60/68.

Authors:  J A Huddleston; G G Brownlee
Journal:  Nucleic Acids Res       Date:  1982-02-11       Impact factor: 16.971

2.  Ubiquitin dependence of selective protein degradation demonstrated in the mammalian cell cycle mutant ts85.

Authors:  A Ciechanover; D Finley; A Varshavsky
Journal:  Cell       Date:  1984-05       Impact factor: 41.582

3.  Improved oligonucleotide site-directed mutagenesis using M13 vectors.

Authors:  P Carter; H Bedouelle; G Winter
Journal:  Nucleic Acids Res       Date:  1985-06-25       Impact factor: 16.971

4.  General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes.

Authors:  M Mackett; G L Smith; B Moss
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

5.  Identification of the sequence responsible for the nuclear accumulation of the influenza virus nucleoprotein in Xenopus oocytes.

Authors:  J Davey; N J Dimmock; A Colman
Journal:  Cell       Date:  1985-03       Impact factor: 41.582

6.  Antigenic variation of influenza A virus nucleoprotein detected with monoclonal antibodies.

Authors:  K L van Wyke; V S Hinshaw; W J Bean; R G Webster
Journal:  J Virol       Date:  1980-07       Impact factor: 5.103

7.  Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells.

Authors:  J R Bennink; J W Yewdell; G L Smith; C Moller; B Moss
Journal:  Nature       Date:  1984 Oct 11-17       Impact factor: 49.962

8.  Recognition by cytotoxic T lymphocytes of cells expressing fragments of the SV40 tumor antigen.

Authors:  L R Gooding; K A O'Connell
Journal:  J Immunol       Date:  1983-11       Impact factor: 5.422

9.  Cytolytic T lymphocyte and antibody responses to synthetic peptides of influenza virus hemagglutinin.

Authors:  M A Wabuke-Bunoti; A Taku; D P Fan; S Kent; R G Webster
Journal:  J Immunol       Date:  1984-10       Impact factor: 5.422

10.  The influenza A virus nucleoprotein gene controls the induction of both subtype specific and cross-reactive cytotoxic T cells.

Authors:  A R Townsend; J J Skehel
Journal:  J Exp Med       Date:  1984-08-01       Impact factor: 14.307

View more
  96 in total

1.  The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses.

Authors:  K Schwarz; R de Giuli; G Schmidtke; S Kostka; M van den Broek; K B Kim; C M Crews; R Kraft; M Groettrup
Journal:  J Immunol       Date:  2000-06-15       Impact factor: 5.422

Review 2.  Role of class I molecules of the major histocompatibility complex in cytotoxic T-cell function in health and disease.

Authors:  A J McMichael
Journal:  Springer Semin Immunopathol       Date:  1992

Review 3.  Cellular mechanisms of antigen processing and the function of class I and II major histocompatibility complex molecules.

Authors:  C V Harding; E R Unanue
Journal:  Cell Regul       Date:  1990-06

4.  Induction of single and dual cytotoxic T-lymphocyte responses to viral proteins in mice using recombinant hybrid Ty-virus-like particles.

Authors:  G T Layton; S J Harris; J Myhan; D West; F Gotch; M Hill-Perkins; J S Cole; N Meyers; S Woodrow; T J French; S E Adams; A J Kingsman
Journal:  Immunology       Date:  1996-02       Impact factor: 7.397

5.  DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction.

Authors:  F Rodriguez; J Zhang; J L Whitton
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

6.  Vaccinia virus infection induces dendritic cell maturation but inhibits antigen presentation by MHC class II.

Authors:  Yongxue Yao; Ping Li; Pratibha Singh; Allison T Thiele; David S Wilkes; Gourapura J Renukaradhya; Randy R Brutkiewicz; Jeffrey B Travers; Gary D Luker; Soon-Cheol Hong; Janice S Blum; Cheong-Hee Chang
Journal:  Cell Immunol       Date:  2007-08-02       Impact factor: 4.868

7.  Effects of rapid antigen degradation and VEE glycoprotein specificity on immune responses induced by a VEE replicon vaccine.

Authors:  M E Fluet; A C Whitmore; D A Moshkoff; K Fu; Y Tang; M L Collier; A West; D T Moore; R Swanstrom; R E Johnston; N L Davis
Journal:  Virology       Date:  2007-09-27       Impact factor: 3.616

8.  Virus-encoded ectopic CD74 enhances poxvirus vaccine efficacy.

Authors:  Crystal C Walline; Sarah N Deffit; Nan Wang; Lynette M Guindon; Victoria L Crotzer; Jianyun Liu; Kristin Hollister; Laurence C Eisenlohr; Randy R Brutkiewicz; Mark H Kaplan; Janice S Blum
Journal:  Immunology       Date:  2014-04       Impact factor: 7.397

9.  An unexpectedly labile mitochondrially encoded protein is required for Mta expression.

Authors:  A C Han; J R Rodgers; R R Rich
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

10.  Simultaneous binding of PA28 and PA700 activators to 20 S proteasomes.

Authors:  K B Hendil; S Khan; K Tanaka
Journal:  Biochem J       Date:  1998-06-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.